P/E at 29.78 vs Industry's 36.52: What the Data Shows for Dr Reddys Laboratories Ltd

Valuation Picture: Discounted P/E Amid Sector Premiums

Dr Reddys Laboratories Ltd currently trades at a P/E of 29.78, which is approximately 18.5% below the Pharmaceuticals & Biotechnology industry average of 36.52. This discount suggests the market is pricing in either subdued growth expectations or elevated risks relative to peers. Given the sector’s generally elevated valuations, the stock’s lower P/E could reflect concerns about recent earnings momentum or broader sector headwinds. The valuation gap invites the question previously rated Hold, what is Dr Reddys Laboratories Ltd's current rating? This valuation tension is a critical factor for investors weighing the stock’s prospects.

Performance Across Timeframes: Divergent Momentum Signals

Examining returns across multiple timeframes reveals a nuanced performance profile. Over the past year, Dr Reddys Laboratories Ltd has declined by 12.43%, underperforming the Sensex’s 9.71% fall. The divergence widens over the three-month period, where the stock has lost 10.14%, significantly worse than the Sensex’s 3.16% decline. However, the one-week and one-month returns show a more mixed picture, with a modest 0.38% gain over one week contrasting with a 4.53% loss over one month, both roughly in line with sector trends. This short-term resilience amid medium-term weakness raises the question is this a genuine recovery or a relief rally that will fade at the 50 DMA? The data suggests investors are grappling with conflicting signals on momentum.

Moving Average Configuration: Bearish Technical Setup

The technical picture for Dr Reddys Laboratories Ltd remains firmly bearish. The stock is trading below all key moving averages — the 5-day, 20-day, 50-day, 100-day, and 200-day — indicating sustained downward pressure. This configuration typically signals a continuation of the downtrend rather than a recovery phase. The absence of any short-term moving average support suggests that recent price action has failed to gain traction, reinforcing the medium-term underperformance observed in returns. The 2-day consecutive fall, with a cumulative loss of 1.73%, further underscores the current negative momentum.

Sector Context: Mixed Results Amidst Pharmaceuticals & Biotechnology

The Pharmaceuticals & Biotechnology sector has delivered a mixed bag of results in the latest reporting cycle. Out of 28 stocks that declared results, 13 posted positive outcomes, 11 remained flat, and 4 reported negative results. This distribution highlights a sector grappling with uneven earnings momentum, which may be contributing to the cautious valuation of Dr Reddys Laboratories Ltd. The stock’s underperformance relative to the sector and the Sensex over one and three years — with 1-year returns at -12.43% versus the Sensex’s -9.71%, and 3-year returns at -1.45% against the Sensex’s 9.65% — reflects challenges that are not isolated but part of broader sector dynamics.

Rating Reassessment: From Hold to Sell

On 13 Jul 2026, the rating for Dr Reddys Laboratories Ltd was updated from Hold to a Sell grade, reflecting a reassessment of the stock’s outlook based on recent data. The Mojo Score stands at 30.0, indicating a cautious stance. This change aligns with the stock’s underperformance relative to the Sensex and sector, as well as its unfavourable technical positioning. The rating update invites investors to consider should investors in Dr Reddys Laboratories Ltd hold, buy more, or reconsider? The data-driven approach behind this reassessment underscores the importance of integrating valuation, performance, and technical factors.

Longer-Term Performance: Lagging Behind Benchmarks

Looking beyond the immediate horizon, Dr Reddys Laboratories Ltd has underperformed the Sensex over multiple longer-term periods. The 5-year return of 16.35% trails the Sensex’s 25.77%, while the 10-year return of 82.09% is significantly below the Sensex’s 160.09%. This persistent lag suggests structural challenges or slower growth relative to the broader market. The stock’s mid-cap market capitalisation of ₹95,787.91 crores places it in a competitive segment of the Pharmaceuticals & Biotechnology sector, where growth and innovation are critical drivers of outperformance.

Intraday and Recent Price Action

On 16 Sep 2026, the stock opened at ₹1,140.95 and has traded around this level, closing with a marginal decline of 0.19%. This underperformance relative to the sector’s intraday gain of 0.60% highlights the stock’s current weakness. The two-day consecutive decline and trading below all major moving averages reinforce the bearish technical outlook. The stock’s relative underperformance today by 0.79% compared to the sector further emphasises the cautious sentiment prevailing among market participants.

Summary: What the Data Collectively Shows

The data for Dr Reddys Laboratories Ltd reveals a stock trading at a valuation discount to its sector, yet suffering from sustained underperformance across multiple timeframes. The technical setup remains bearish, with the stock below all major moving averages and recent consecutive declines. Sector results are mixed, reflecting broader challenges in Pharmaceuticals & Biotechnology. The rating reassessment from Hold to Sell on 13 Jul 2026 aligns with these trends, signalling a cautious stance. Investors may find it prudent to evaluate what is the current rating for Dr Reddys Laboratories Ltd? in light of this comprehensive data analysis.

Only Rs. 9,999 - Get MojoOne + Stock of the Week for 1 Year Start at 33% Off →